Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations Feb 8, 2022
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day Jan 31, 2022
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January Jan 5, 2022
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330 Dec 8, 2021
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM) Nov 23, 2021
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update Nov 12, 2021
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting Nov 1, 2021
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases Oct 7, 2021
Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting Oct 1, 2021
